Capital Group Private Client Services Inc. Has $12.69 Million Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital Group Private Client Services Inc. cut its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 4.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,783 shares of the company’s stock after selling 1,945 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in BeOne Medicines were worth $12,694,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ONC. Cetera Investment Advisers acquired a new stake in BeOne Medicines in the second quarter valued at $455,000. Rhumbline Advisers acquired a new stake in BeOne Medicines in the second quarter valued at $275,000. Arrowstreet Capital Limited Partnership acquired a new stake in BeOne Medicines in the second quarter valued at $505,000. Invesco Ltd. acquired a new stake in BeOne Medicines in the second quarter valued at $422,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in BeOne Medicines in the second quarter valued at $68,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $270.10 on Friday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $301.86 and a two-hundred day moving average price of $317.87. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22. The company has a market cap of $29.64 billion, a P/E ratio of 60.43 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. As a group, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ONC shares. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price objective for the company from $420.00 to $290.00 in a report on Monday, March 16th. Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday. Leerink Partners increased their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Wells Fargo & Company started coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

Insiders Place Their Bets

In other BeOne Medicines news, Director Alessandro Riva sold 212 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.51, for a total transaction of $65,616.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Margaret Dugan sold 212 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.60, for a total value of $65,635.20. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 1,641 shares of company stock valued at $505,791. 6.19% of the stock is currently owned by insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.